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Introduction
Adenosine plays an important role in coupling energy supply to energy demand
and exerts its effects via four subtypes of adenosine receptors named adenosine
A1, A2A, A2B and A3 receptors. These receptors all belong to the family of 7 trans-
membrane receptors (TM7) that predominantly signal through activation of G-
proteins [17]. Although adenosine A1 and A3 receptors were originally reported
to couple to Gi/o protein and the adenosine A2 receptors to Gs protein, it is now
clear that this is not exclusively the case [17]. Adenosine receptors have been
cloned from various species and their pharmacological profile is based on a
variety of specific agonists and antagonists [17, 23].
Under physiological conditions adenosine acts as an inhibitory neuromodulator in
the brain [10, 42]. Neuropathological conditions like stroke, ischemia and
seizures lead to the release of large amounts of adenosine in the extracellular
space. Under these conditions adenosine acts as a neuroprotective agent and an
endogenous anticonvulsant [13, 15].  Adenosine promotes neuronal survival and
moreover counteracts seizure activity by presynaptically inhibiting the release of
the excitatory neurotransmitter glutamate [33, 34]. Postsynaptically, adenosine
causes hyperpolarization of the cell membrane, mainly by increasing K+
conductance [19, 40]. These actions of adenosine are mainly mediated by
adenosine A1 receptors. Accordingly, the neuroprotective effect of adenosine will
be increased by upregulation of adenosine A1 receptors [34]. 
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The neuromodulator adenosine is released in the brain in large amounts during neuropathological
events, like stroke or seizures. Under these circumstances adenosine induces neuroprotective
effects by activating adenosine A1 receptors in neurons. This makes the adenosine system one of
the most important neuroprotective systems in the brain. Significant upregulation of adenosine A1
receptor expression has been shown in mice after seizures, thereby increasing the neuroprotective
function of adenosine. This upregulation is a rather unusual feature, since G-protein coupled
receptors are normally down regulated in the presence of large amounts of ligand. We propose
here a mechanism that induces upregulation of adenosine A1 receptor expression in the presence
of high concentrations of extracellular adenosine.
In vitro experiments have shown that stimulation of glia cells with the pro-inflammatory cytokine,
interleukin-6 (IL-6) leads to an increase of adenosine A1 receptor expression in cultured brain
cells. In order to investigate the role of IL-6 in adenosine A1 receptor upregulation after seizures
we have performed experiments in wild type and IL-6 knock out mice. We report that wild type
mice show increased expression of adenosine A1 receptors in hippocampus and cortex after
pentylenetetrazole-induced seizures, measured by autoradiography. In contrast, no upregulation
was observed in IL-6 knock out mice. These results suggest that IL-6 is involved in the
upregulation of adenosine A1 receptor expression after seizures. We conclude that IL-6 plays an
important role in the complex mechanism of adenosine-induced neuroprotection.Upregulation of adenosine A1 receptors in the brain has been observed in mouse
and rat after induction of seizures and in post mortem tissue of humans suffering
from epilepsy [5, 30, 41]. It has moreover been assumed that in mice this
upregulation of adenosine A1 receptors protects neurons against subsequent
seizures [4]. However, the observed upregulation of adenosine A1 receptors in
the presence of high concentrations of extracellular adenosine is a rather unusual
feature, since TM7 receptors are normally downregulated (desensitized) in the
presence of large amounts of ligand [21, 36]. Indeed, desensitization of adenosine
A1 receptors in response to prolonged agonist treatment in brain tissue has been
reported [1, 2, 36]. It may thus be assumed that the expression of adenosine A1
receptors during seizures is regulated such that the desensitizing properties of
high adenosine concentrations are counteracted. We have recently suggested a
mechanism that involves the cytokine IL-6, which could account for such an
upregulation [8]. IL-6 is released in brain under pathological conditions like
ischemia and seizures [26, 28, 31] where it is known to have significant
neuroprotective effects [3, 18, 25, 39]. Previous work from our group has shown
that adenosine induces the release of IL-6 in astrocytes [16, 38] and that IL-6
treatment increases adenosine A1 receptor expression in nervous tissue [8]. 
A direct relationship between IL-6 expression in brain and upregulation of
adenosine A1 receptors in vivo has yet not been demonstrated. In order to address
this question we have now investigated the potential role of IL-6 in regulating
adenosine A1 receptor expression in vivo, using IL-6 deficient mice. We report
here that the increased expression of adenosine A1 receptors, observed in the
hippocampus and cortex of wild type mice in response to pentylenetetrazole-
induced seizures is absent in IL-6 deficient mice. This finding corroborates the
assumption that IL-6 increases A1 receptor expression in brain. 
Materials and Methods
Animals and pentylenetetrazole treatment
Male wild type C57Bl6 mice (Harlan) and male IL-6 knock out mice (Jackson), 3
months old, weighing 23-29 g were used. The animals were housed in groups of
five per cage in a room with controlled light/dark (12h/12h) cycle and
temperature (21ºC). Food and water was supplied ad libitum. The mice received
once daily, for two consecutive days one intraperitoneal (i.p.) injection with 55
mg/kg pentylenetetrazole (PTZ, Sigma) dissolved in 0.9% saline solution.
Control animals received saline only. Latency of seizure onset was timed and
animals were subsequently observed for one hour. Animals were assigned a
seizure score according to the following criteria adopted from Kondziella and
colleagues [24]. 0= normal behavior, 1= myoclonic jerks, 2= minimal seizures
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clonic seizures, 5= like 4 with loss of consciousness and postictal phase, 6= like
5 with rotation on their axis, 7= like 6 and death. All pentylenetetrazole (PTZ)
treated animals showed at least score 2 (minimal seizures) within 5 minutes.
Mice were killed by decapitation 26 hours after the second injection. All
experiments were in accordance with the regulations of the Committee for Use of
Experimental Animals of the University of Groningen (DEC No. 2976).
The mice which received PTZ injections did not all show tonic-clonic seizures.
Therefore, the groups of mice (both wild type and IL-6 knock out) that received
PTZ injections, were subdivided in two groups according to the severity of the
seizures. The “PTZ-high” groups consisted of animals which showed tonic-clonic
seizures (score 4) after at least one of the two PTZ injections. All other animals,
which received PTZ injections, were assigned to the “PTZ-low” groups.
Tissue preparation
The brains were removed immediately after decapitation. The two hemispheres
were separated and subsequently frozen and stored at –80ºC until use. The right
hemispheres were prepared for RNA analysis and radioligand binding studies
while the left hemispheres were used for autoradiography. 
The right hemispheres of animals in the same experimental group were pooled
before RNA extraction and membrane preparation. Wild type and IL-6 knock out
control groups contained 15 animals, while the four PTZ treated groups had 6-8
animals per group. From the right hemispheres 25 coronal brain sections of 30 µm
were cut and lysed in guanidinium isothiocyanate containing mercaptoethanol.
Lysed samples were stored at -20ºC until RNA analysis. The remaining part of the
right hemispheres was collected in 0.32 M sucrose solution (4ºC) and immediate-
ly processed further into brain membranes according to Lohse and colleagues
[29]. In brief, brain tissue was homogenized using a Potter-homogenizer in 10
volumes of 0.32 M sucrose. The homogenate was centrifuged at 1000 g for 15 min
and the supernatants were centrifuged at 48000 g for 40 min. The pellets were
resuspended in 50 mM Tris-HCl buffer, pH 7.4, and subsequently centrifuged at
48000 g for 15 min.  After repeating the last centri-fugation step membranes were
resuspended in Tris-HCl buffer and incubated at 37ºC for 30 min with 2 IU/ml
adenosine deaminase. Brain membranes were frozen and stored at –80ºC until
the binding assay was performed. 
Left hemispheres were cut into coronal brain sections of 20 µm using a Leica
microtome (at -14ºC). The tissue sections were thaw-mounted on gelatine-coated
microscope slides and dried overnight sealed in plastic with silica gel. Microscope
slides were stored at –80ºC until autoradiography. 
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Tissue was lysed in guanidinium isothiocyanate/mercaptoethanol buffer and total
RNA was extracted with one phenol/chloroform step according to [9].
Subsequently, RNA was treated with RNAse free DNAse (Sigma-Aldrich,
Bornhem, Belgium) for 30 min and precipitated. Reverse transcription (RT): 1 µg
of total RNA was transcribed into cDNA in a total volume of 25 µl containing 0.5
µl of M-MLV reverse transcriptase, 1 µl of RNase inhibitor, 1 µl of random
hexamers (0.2 mM), 5 µl of 5x buffer, 1.25 µl of deoxynucleosidetriphosphates
(dNTPs) (10 mM) and H2O adjusted to 25 µl. After 60 min at 42°C, the reaction
was stopped by heating at 95°C for 5 min. The quality of the cDNA was
controlled using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers
(see Table 5.1). Potential contamination by genomic DNA was checked for by
running the reactions without reverse transcriptase and using GAPDH primers in
subsequent polymerase chain reaction (PCR) amplifications. Conventional PCR:
2 µl of the RT reaction was used in subsequent PCR amplification as described
previously [7]. In brief, the following reagents were added: 5 µl 10x PCR-buffer,
2.5 µl MgCl2 (50 mM), 0.5 µl dNTPs (10 mM), 1 µl of a mix containing both
primers, 39 µl H2O and 0.1 µl Taq-polymerase. 
Real-time semi-quantitative polymerase chain reaction (Q-PCR)
Adenosine A1 receptor mRNA expression in the brains of wild type and IL-6
knock out mice was analyzed by real-time PCR using the iCycler (Bio-rad,
Veenendaal, The Netherlands) and the iQ SYBR Green supermix (Bio-rad).
Mouse ribosomal protein L32-3A (rpL32A) primers and hypoxanthine guanine
phosphoribosyl transferase (HPRT1) primers were used for normalization to
housekeeping genes. These genes did not show variations in response to the
experimental treatment. Primers used for adenosine A1 receptor analysis and the
housekeeping gene primers, listed in table 5.1, have been designed by the use of
the Primer Designer program (Scientific and Educational Software, Version 3.0).
The comparative Ct method (amount of target amplicon X in sample S,
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Table 5.1. Primers used for conventional reverse transcriptase and real-time (*) PCR
Gene accession  Forward primer (5’-3’) Backward primer (5’-3’) Product
number   size(bp)
GAPDH AF106860 CATCCTGCACCACCAACTGCTTAG GCCTGCTTCACCACCTTCTTGATG 346
rpL32A* X06483 GCTGGAGGTGCTGCTGATGT ACTCTGATGGCCAGCTGTGC 114
HPRT1* X62085 GACTTGCTCGAGATGTCA TGTAATCCAGCAGGTCAG 102
Ado A1R* AJ555877 CCTCTCCGGTACAAGACAGT GGTGTCAGGCCTACCACAAG 92normalized  to  a  reference R  and  related  to a control sample C,  calculated by
2-{(CtX,S-CtR,S)- (CtX,C-CtR,C)} was used to determine the relative expression levels
between animal groups treated with saline and PTZ [27]. Results are given as
mean ± S.E.M. (n=4). Relative expression values of adenosine A1 receptor
mRNA in animal groups treated with PTZ were compared to control levels (saline
treatment) by the one-sample t test, using 1 as the test value. p < 0.05 was
considered significant. 
Radioligand binding assay
For the determination of the maximum bound radioligand, membranes were
incubated for 1 hr at 25°C in 50 mM Tris/HCl (pH 7.4 at 25°C) in the presence of
4 nM [3H]DPCPX (Ki = 1.4 nM). Experiments were performed three times in
triplo. Aspecific binding was determined in the presence of 100 µM CPA. Total
volume during incubation was 200 µl. The protein concentration was measured in
the suspension used in the different experiments with the bicinchonic acid
method. Incubations were stopped by rapid dilution with 1 ml ice-cold buffer and
bound radioligand was subsequently recovered by filtration through Whatman
GF/B filters using either Millipore system or Brandel Harvester under reduced
pressure. Filters were then washed three times with 2 ml buffer. The retained
radioactivity was measured by liquid scintillation counting (LKB Wallac, 1219
Rackbeta).
Autoradiography
Sections were preincubated in Tris-HCl buffer, 170 mM, pH 7.4 containing 0.5
IU/ml adenosine deaminase (Sigma Co.) for 3 x 10 min at room temperature,
washed out and dried in a stream of cold air. For the labeling of adenosine A1
receptors, sections were incubated with 3.0 nM [3H]- N6-cyclohexyladenosine
([3H]-CHA, Moravek Biochemicals, Brea, CA, USA, spec. activity 20 Ci/mmol) in
170 mM Tris-HCl buffer including 0.5 IU/ml adenosine deaminase at room
temperature for 90 min. To determine non-specific binding sections were
incubated in the presence of 3 µM N6-cyclopentyladenosine (CPA, Sigma-RBI,
Saint Louis, MA, USA). Following incubation, unbound radioactivity was
removed by rinsing the sections three times for 2 min in ice-cold Tris-HCl buffer,
50 mM, pH 7.4, and rinsing once for 5 s in ice-cold distilled water to remove
buffer salts. The sections were then dried in a stream of cold air. 
Dried sections were exposed to a tritium-sensitive phosphor screen (Packard)
along with tritium standards ([3H]-microscales, Amersham) and stored in an X-
ray film cassette for 96 hours at room temperature. Screens were read using the
Cyclone Storage Phosphor system (Packard). Quantification analysis of the
resulting autoradiographic images was performed by using an automatic image
analysis system (Quantimet 500, Leica, Cambridge). Optical density was measured
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areas measured). The values of the sections were averaged for each mouse.
Optical density measurements from each brain area were converted into fmol
ligand bound per mg tissue equivalent, according to the calibration curve
obtained from the tritium standards. Statistical comparisons of the four animal
groups were performed using one-way ANOVA followed by Tukey posthoc test.
Results
Seizure scores
Seizure scores consist of ordinal data, therefore an average seizure score per
group is not informative on the actual seizure scores. We therefore compared the
seizure severity after the first and second PTZ-injection per animal. Figure 5.2
shows the percentage of animals with similar seizure scores after both PTZ-
injections and animals that showed higher scores after the first injection or after
the second injection. In wild type mice one animal showed lower seizure scores
after the second injection. The majority of animals (7 out of 10 animals) showed
equal seizure scores on both days and in two animals higher seizure scores after
the second injection were found. This pattern was different in IL-6 deficient mice,
where the majority of animals (7 out of 13 animals) showed higher scores after
IL-6-induced upregulation of adenosine A1 receptor expression
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Figure 5.1. Overview of the brain areas measured with autoradiography. Autoradiography was
performed as described in the methods part. Adenosine A1 receptor expression was measured in
one area of the hippocampus, which showed high expression of adenosine A1 receptor (area 1) and
in two areas of the cortex. Area 2 included the parietal/somatosensory cortex while area 3 included
the piriform cortex. All sections in which adenosine A1 receptor expression was measured were
taken at approximately Bregma –1.75. the second injection and the minority showed equal (5 out of 13) or lower seizure
scores (1 out of 13) after the second PTZ-injection. In order to compare the
scores after first and second injection statistically, the Wilcoxon signed ranks test
was used. IL-6 knock out mice showed significantly (p < 0.05) higher seizure
scores after the second injection compared to the first, whereas no significant
difference in seizure scores between the two injection rounds was observed in
wild type animals. 
Adenosine A1 receptor mRNA expression 
In order to investigate possible effects of seizure activity in IL-6 deficient mice and
wild type animals on A1 receptor mRNA expression, Q-PCR analysis was
performed. No differences were observed in mice with lower seizure scores
compared to control mice (data not shown). Similarly no seizure effect on A1
receptor expression was measured in wild type with high seizures scores compared
to untreated mice (Figure 5.3). In contrast a significant (p < 0.05) downregu-
lation of adenosine A1 receptor mRNA expression was detected in IL-6 deficient
mice with high seizure scores compared to untreated controls (Figure 5.3).
Adenosine A1 receptor expression in brain membranes (radioligand binding)
Radioligand binding experiments using [3H]DPCPX have been performed in
order to investigate the expression of adenosine A1 receptors in the brain. The
use of [3H]DPCPX as a specific mouse adenosine A1 receptor binding molecule
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Figure 5.2. Comparison of seizure scores of wild type and IL-6 knock out after first and second
PTZ-injection. Day 1>2 indicates higher seizure scores on day 1; 1=2 indicates no differences in
seizure scores between the two injections; 1<2 indicates that the observed seizure score on day 2
was higher than on day 1. Statistical analysis using the wilcoxan signed ranks test showed that IL-6
knock out mice showed significantly higher scores on day 2 compared to day 1 while wild type
animals showed similar scores on both days.has been evaluated in an earlier study [43]. Since a high concentration (3 times of
the Ki) of the radioligand was used, one can assume that all adenosine A1
receptors present in the preparation will be occupied by the ligand. Therefore the
amount of [3H]DPCPX binding is informative on the number of adenosine A1
receptors. The graph in figure 5.4 shows [3H]DPCPX binding in fmol per mg
tissue in wild type animals and IL-6 deficient mice. In IL-6 knock out mice there
are no differences between control and PTZ-injected animals (both PTZ low score
and PTZ high score). Similarly we did not observe a difference in [3H]DPCPX
binding between the PTZ low score group and control wild type animals. In wild
type mice that showed high seizure scores after PTZ injection more [3H]DPCPX
binding was observed. This difference, however, just failed to reach significance,
which is most likely due to the fact that seizures do not upregulate adenosine A1
receptor expression in all brain regions [4, 30]. It was therefore further decided to
investigate the seizure effects in autoradiographic experiments as described [4].
Since animals which showed low seizure scores, did not show any sign of
increased [3H]DPCPX binding only animals with high seizure scores were used
for autoradiography experiments.
IL-6-induced upregulation of adenosine A1 receptor expression
97
0.9
0.7
1.0
1.1
0.8
r
e
l
a
t
i
v
e
 
a
d
e
n
o
s
i
n
e
 
A
1
 
m
R
N
A
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
 
(
r
a
t
i
o
 
P
T
Z
/
c
o
n
t
r
o
l
)
wild type
*
IL-6 KO
Figure 5.3. Real-time PCR analysis of adenosine A1 receptor mRNA expression in brains of wild
type and IL-6 knock out mice (normalized to rpl32A and HPRT1). Graph shows the relative
expression level of mRNA in PTZ-injected animals (“PTZ high score”) compared to controls. The
expression level of controls is set to 1. Data represent mean ± S.E.M of 4 experiments. * =
significant reduction of mRNA expression compared to controls (p < 0.05), measured with the
one-sample T-test.Adenosine A1 receptor expression in brain sections (autoradiographic
analysis)
Figure 5.5 shows the results of the autoradiography experiments. We investigated
adenosine A1 receptor expression in the hippocampus and cortex, brain regions
that showed an upregulation of adenosine A1 receptors in response to PTZ-
induced seizures [4, 30]. In hippocampus (Figure 5.5A) and cortex (parietal/
somatosensory cortex) (Figure 5.5B) of wild type mice a significant upregulation
(p < 0.05) of [3H]CHA binding was observed in response to seizures. These
findings indicate an upregulation of adenosine A1 receptor expression of
approximately 20% resembling values found in an earlier study [30]. In striking
contrast no upregulation of adenosine A1 receptor expression was observed in IL-
6 knock out mice, thereby corroborating the results obtained in membrane
preparations. In another area of the cortex (including the piriform cortex) no
differences in [3H]CHA binding were observed in both animal groups, wild type
mice and IL-6 knock out animals (Figure 5.5C).
Correlation between seizure scores and adenosine A1 receptor expression
By plotting the seizure scores against the [3H]CHA binding results of the
autoradiography experiments of individual animals, a possible correlation
between seizure score (after the first PTZ-injection) and adenosine A1 receptor
expression was investigated (Figure 5.6). Data of both control (which all had
seizure score 0) and PTZ treated animals (score 2-4) were plotted. Statistical
analysis revealed that the Pearson’s correlation coefficient was significant; p =
0.003 (hippocampus) and p = 0.0019 (cortex1), indicating a positive correlation
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Figure 5.4. Specific radioligand [3H]DPCPX binding to adenosine A1 receptors in brain
membranes of wild type and IL-6 knock out mice. Data are represented as mean ± S.E.M. of 3
experiments. No significant differences could be found using one-way ANOVA.between seizure scores observed on day 1 and [3H]CHA binding in wild type
animals (Figure 5.6A and C respectively). No significant correlations were found
in IL-6 knock out animals (Figure 5.6B and D). It was also clear that the two wild
type animals that showed lower seizure scores (2 and 3) after PTZ injection also
had lower adenosine A1 receptor expression levels. 
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Figure 5.5. Autoradiographic analysis of adenosine A1 receptor expression in brain areas of wild
type and IL-6 knock out mice. Graphs show [3H]CHA binding in hippocampus (A), cortex 1 (B)
and cortex 2 (C). Data are represented as mean ± S.E.M. per group (6-8 animals per group). * =
significant increase in adenosine A1 receptor expression in hippocampus (A) and cortex 1 (B);
p<0.05 using one-way ANOVA followed by Tukey post-hoc test.Discussion
The current experiments were aimed to investigate the potential regulatory effect
of IL-6 on the expression of adenosine A1 receptors in brain tissue. Both
adenosine and IL-6 are released under neuropathological conditions like seizures
[26, 31, 32, 34, 37] and both factors induce pronounced neuroprotection [14, 18,
25, 28, 35]. However, in contrast to the well-understood neuroprotective effects
of adenosine the mechanism of IL-6-induced neuroprotection remains to be
elucidated [18, 20].
The main receptor involved in the neuroprotective effect of adenosine is the
adenosine A1 receptor [14, 34] and it has long been known that an upregulation
of its expression increases its neuroprotective capacities [34]. Accordingly, a
Chapter 5
100
B A
120
100
[
3
H
]
 
C
H
A
 
b
i
n
d
i
n
g
 
i
n
 
c
o
r
t
e
x
 
1
(
i
n
 
f
m
o
l
/
m
g
 
t
i
s
s
u
e
)
60
wild type
C
80
100
120
0
seizure score on day 1
1234
D
0
seizure score on day 1
1234
[
3
H
]
 
C
H
A
 
b
i
n
d
i
n
g
 
i
n
 
h
i
p
p
o
c
a
m
p
u
s
(
i
n
 
f
m
o
l
/
m
g
 
t
i
s
s
u
e
)
140
160
IL-6 KO
Figure 5.6. Adenosine A1 receptor expression in wild type mice is correlated to seizure scores
after the first PTZ-injection. Correlation analysis of adenosine A1 receptor expression and seizure
scores were performed by plotting the expression data against the seizure scores. Each data point
in the graphs represents an individual animal. Regression lines were calculated using Sigma Plot
8.0. Positive correlations were found between adenosine A1 receptor expression in hippocampus
and cortex area 1 and seizure scores induced by the first PTZ-injection in wild type animals (A, C)
but not in IL-6 knock out animals (B, D).marked adenosine A1 receptor upregulation has been observed in mice and rats
by chemically induced seizures and in post mortem tissue of humans suffering
from epilepsy. In all cases this upregulation is assumed to protect neurons against
subsequent seizures [4, 5, 30, 41]. The upregulation of adenosine A1 receptors
during seizures presents a paradox, since adenosine A1 receptors have been found
to be downregulated by prolonged ligand treatment [1, 2, 21, 36]. We have
recently described an upregulating effect of IL-6 treatment on adenosine A1
receptor expression in vitro and proposed that the cytokine could explain the
increased expression of A1 receptors after seizures [8]. In order to evaluate this
hypothesis we have induced seizures in IL-6 deficient mice and wild type mice
and compared the expression of adenosine A1 receptors in brain.
First, we found that IL-6 deficient mice showed higher seizures scores after the
second injection compared to the first injection, whereas this was not the case in
wild type animals. Moreover, two animals in the IL-6 deficient group died as a
result of PTZ induced seizures, whereas all wild type animals survived the
procedure. These findings suggest that IL-6 knock out mice are more susceptible
to PTZ induced seizures, which was also concluded in two very recent studies
[11, 12]. 
Second, no seizure effect on A1 receptor mRNA expression was found in wild type
mice, whereas PTZ treatment caused a significant down regulation of adenosine
A1 receptor mRNA expression in brain of IL-6 deficient mice. These findings thus
indicate a stimulatory effect of IL-6 on the adenosine A1 receptor mRNA
expression in brain, verifying data that were obtained in vitro previously [8].
Third, using autoradiography we observed a significant increase in adenosine A1
receptor expression in the hippocampus and part of the cortex in wild type mice
after PTZ-induced seizures. In contrast to wild type mice we did not find any
effect of PTZ treatment on the expression of adenosine A1 receptors in the brain
of IL-6 deficient mice. These autoradiographic findings were supported by
radioligand binding experiments in membrane preparations of the brain. Taken
together these findings strongly support our previous assumption that IL-6
increases the expression of adenosine A1 receptors in nervous tissue [8]. 
In a recent paper it was shown that seizures could be induced in IL-6 knock out
mice at much lower dosages of several convulsant substances when compared to
wild type littermates [12]. By analyzing the effect of these different convulsants
the authors conclude that IL-6 knock out mice might have impaired GABA
inhibitory inputs and enhanced neurotransmission through glutamate receptors.
Since adenosine A1 receptors are regulating both transmitter systems [14], we
suggest that IL-6 knock out mice are more susceptible to seizures due to a lack of
adenosine A1 receptor upregulation. 
Stimulation of adenosine A1 receptor expression might not be the only
connection between IL-6 and the adenosinergic system. We and others have
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synthesis and release of IL-6 [16, 38]. Since adenosine A2B receptors have a low
affinity for adenosine, high concentrations of the ligand (which are found during
seizures) are required to activate this receptor. We therefore propose the
following sequence of events: high concentrations of adenosine (like in seizures)
activate adenosine A2B receptors in astrocytes and lead to the release of IL-6,
which in turn increases the expression of adenosine A1 receptors augmenting the
neuroprotective properties of this receptor [8]. 
Interestingly, a significant correlation was found in this study between the seizure
scores and the induction of adenosine A1 receptor expression in the hippocampus
and cortex of wild type mice. Thus, increased expression of adenosine A1
receptors was only found in animals with high seizure scores. Since according to
the above mentioned assumptions high levels of extracellular adenosine are
required to initiate the circuitry, it is tempting to speculate that only in animals
with high seizure scores a sufficient amount of adenosine was released to
stimulate the synthesis of IL-6. However, in order to confirm this hypothesis,
further experiments are needed that would investigate the correlation of seizure
severity and IL-6 release in the brain.
The data presented here and the results of others strongly suggest a beneficial
role of the pro-inflammatory cytokine IL-6 in brain during seizures. Findings
pointing in the same direction have been published earlier by Asanuma and
colleagues [6]. This group found that an inhibition of brain inflammation by
cyclosporine A treatment, which blocks the expression of several inflammatory
genes [22], significantly aggravated the severity of PTZ-induced seizures.
Interestingly, it was observed that cyclosporine A treatment only affected seizure
activity after the second PTZ injection very similar to the effect we observed in IL-
6 deficient mice [6]. These authors concluded that the brain inflammation
occurring in response to the first seizures would initiate processes that protect
the brain from upcoming seizure events. We have now added data in support of
this assumption, showing that inflammatory events (release of IL-6) upregulate
the expression of the adenosine A1 receptor. 
We and others found that seizures did not induce an increase in adenosine A1
receptor expression in all brain regions [30]. Due to our data it would therefore
be of particular interest to investigate the question whether brain regions without
an effect on A1 receptor expression might have different IL-6 release capacities or
whether the expression of A1 receptors is differentially regulated. 
In conclusion, this study demonstrates a clear relationship between the expression
of IL-6 and the upregulation of adenosine A1 receptors in response to seizures.
The current data not only verify findings that have been obtained in vitro, they
moreover provide an explanation for the well-known, but not well-understood
neuroprotective properties of IL-6. 
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